Previous studies have shown that pancreatic cancer has high-affinity MHC class I-restricted neo-epitopes, and the CD155/TIGIT signal axis is sufficient to facilitate immune evasion mediated by pancreatic cancer expressing neo-epitopes (24). This evidence concerns the gene PVR and familial pancreatic carcinoma.